ARCHIVES

Taxol Patents Reveal Bristol Strategy to Safeguard Market Against Competitors

This article is from The Cancer Letter archive.

Vol. 23 No. 26 | July 4, 1997

Download PDF Visit The Full Archive

Related Articles

Wyden, Schroeder Bill Would Require NIH To Test RU 486

October 23, 1992

ODAC Reviews Post-Marketing Studies for Eight Indications

February 21, 2003

In Brief: Nutrition Research Intrigues Investigators After All; Advisory Committee Being Formed

March 7, 1975

NCI Cooperative Group Clinical Trials Approved

May 29, 2009

In Brief: First CREG Announcement Due In Late April For In Vitro Carcinogen Test Improvements

March 21, 1975

PFS Is A Benefit “In The Right Context,” Pazdur Says In Q&A On Avastin Approval.

February 29, 2008